Envista (NYSE:NVST) Price Target Raised to $18.00

Envista (NYSE:NVST) had its price target raised by equities research analysts at Piper Sandler from $17.00 to $18.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Piper Sandler’s price target indicates a potential downside of 10.94% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Leerink Partnrs raised shares of Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Thursday, October 31st. Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and upped their price target for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Robert W. Baird boosted their price objective on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, October 31st. Finally, Mizuho initiated coverage on Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price for the company. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $20.21.

Envista Trading Down 1.5 %

NVST stock traded down $0.31 during trading on Monday, reaching $20.21. 919,178 shares of the stock were exchanged, compared to its average volume of 1,816,755. The business has a 50 day moving average price of $20.08 and a 200-day moving average price of $19.04. Envista has a 1 year low of $15.15 and a 1 year high of $24.79. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -2.60, a P/E/G ratio of 1.82 and a beta of 1.34.

Institutional Investors Weigh In On Envista

Hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in Envista in the 3rd quarter valued at $31,000. GAMMA Investing LLC raised its holdings in Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after purchasing an additional 726 shares in the last quarter. Huntington National Bank lifted its position in Envista by 97.8% in the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after purchasing an additional 949 shares during the period. Venturi Wealth Management LLC increased its position in Envista by 528.4% during the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after purchasing an additional 1,638 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of Envista by 69.7% during the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after buying an additional 804 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.